o

Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment




o

Bone Marrow Transplantation




o

NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma




o

Irradiation induces cancer lung metastasis through activation of the cGAS–STING–CCL5 pathway in mesenchymal stromal cells




o

Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells




o

The HMGB1-RAGE axis modulates the growth of autophagy-deficient hepatic tumors




o

QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism




o

WTAP and BIRC3 are involved in the posttranscriptional mechanisms that impact on the expression and activity of the human lactonase PON2




o

LncRNA <i>SNORD3A</i> specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression




o

NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas




o

MicroRNA let-7c (MIRLET7C; let-7c), miR-99a and miR-125b as prognostic markers of luminal breast cancer

Studies in patient samples and cell culture suggest let-7c, miR-99a and miR-125b could serve as prognostic markers in patients with estrogen receptor–positive luminal breast cancers.




o

Chromosome 11 open reading frame 30 (C11orf30), calpain small subunit 1 (CAPNS1; CAPN4), signal transducer and activator of transcription 6 (STAT6) and ankyrin repeat domain 27 (ANKRD27) as diagnostic markers for eosinophilic esophagitis (EoE)

Genomewide association studies identified four genes that could serve as diagnostic markers and/or therapeutic targets for EoE.




o

Tumor-selective delivery of antisense oligomers (antimiRs) against oncogenic microRNAs

miRNA-targeted antimiRs conjugated to a peptide with a low pH–induced transmembrane structure (pHLIP) could help treat solid tumors.




o

RNAi against therapeutic targets with short interfering ribonucleic neutrals (siRNNs)

siRNNs could enable RNAi knockdown of therapeutic targets in a broader range of cells and tissue types than siRNA.




o

Extending therapeutic protein half-lives via fusion to affibodies with pH-dependent binding to neonatal Fc receptor

Fusing therapeutic proteins to affibodies with pH-dependent binding to neonatal Fc receptor could improve the proteins' half-lives.




o

Nanomolar-scale, high throughput chemical synthesis of drug-like molecules

A high throughput, miniaturized chemical synthesis platform could enable rapid discovery of lead compounds.




o

Dermatophagoides pteronyssinus peptidase 1 (DERP1)

In vitro and rat studies suggest inhibiting the enzymatic activity of house dust mite (HDM) allergens could help treat allergic asthma.




o

VEGF receptor (VEGFR)

Zebrafish studies suggest VEGFR inhibitors could help treat tuberculosis.




o

Glutathione peroxidase 4 (GPX4)

Mouse studies suggest inhibiting ferroptosis could help treat ischemia/reperfusion injury in the liver and kidney.




o

Angiopoietin 2 (ANG2; ANGPT2); placental growth factor (PGF; PlGF); tissue inhibitor of metalloproteinases 3 (TIMP3)

Mouse studies suggest inhibiting PGF could help treat hypertension.




o

Sortilin 1 (SORT1)

Mouse studies suggest inhibiting SORT1 in macrophages and T cells could help treat atherosclerosis.




o

Topoisomerase II binding protein 1 (TOPBP1)

Mouse and cell culture studies suggest inhibiting TOPBP1 could help treat cancer.




o

Globohexaosylceramide (globo-H); stage-specific embryonic antigen-3 (SSEA-3); SSEA-4

Mouse studies suggest chemically modified carbohydrate conjugates could be useful as antigens for the development of cancer vaccines.




o

Epidermal growth factor receptor 1 (EGFR1; ErbB1; HER1); HER2 (EGFR2; ErbB2; neu); HER3 (EGFR3; ErbB3); VEGF

Tumor cell and mouse studies suggest tetravalent antibodies that target four different antigens could help treat cancers resistant to HER-targeted therapies.




o

Cyclin dependent kinase 7 (CDK7); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC)

In vitro and mouse studies suggest THZ1, a covalent CDK7 inhibitor, could help treat neuroblastoma and other cancers driven by MYCN and other c-MYC (MYC)-family oncoproteins.




o

Tripartite motif containing 37 (TRIM37)

In vitro and mouse studies suggest inhibiting TRIM37 could help treat breast cancer.




o

Estrogen receptor; LYN kinase (LYN); phosphoinositide 3-kinase (PI3K)

Studies in mice and human samples suggest inhibiting LYN could help treat estrogen receptor–positive breast cancers resistant to anti-estrogen therapy.




o

Genocea's mark on malaria

Genocea has identified an immunological imprint in patients with malaria and is using a $1.2 million grant from the Gates Foundation to turn the findings into a vaccine.




o

Translational tidbits

Yabao and MRC Technology partner in PD; charities form Neuro-MAP to insource pharma's abandoned compounds; Singapore creates a diagnostic hub; a roundup of public-private partnerships.




o

Translational balance

Moving discoveries from academia to industry requires a delicate balance of risk, reward, skill sets and personalities, according to a translational panel held at BIO-Europe's partnering conference.




o

Neutralizing the negatives of RNAi

The siRNN technology that Solstice licensed from UCSD could take RNAi-based therapies to tissues outside the liver and expand their use to a host of new diseases.




o

LIS1 cracks open dynein




o

Pac1/LIS1 stabilizes an uninhibited conformation of dynein to coordinate its localization and activity




o

Tissue-resident ductal macrophages survey the mammary epithelium and facilitate tissue remodelling




o

Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity




o

In vitro capture and characterization of embryonic rosette-stage pluripotency between naive and primed states




o

Bridging naïve and primed pluripotency




o

Differentiation of transplanted haematopoietic stem cells tracked by single-cell transcriptomic analysis




o

FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome




o

Nature Cell Biology




o

Reviewer Recognition




o

Transcription factors in ferroptotic cell death




o

MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis




o

In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses




o

Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice




o

TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials




o

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40




o

UNC5B mediates G2/M phase arrest of bladder cancer cells by binding to CDC14A and P53




o

High-purity orbital angular momentum states from a visible metasurface laser




o

Dark field on a chip